Ai's role in drug development remains uncertain

AI has attracted significant investment in drug development, with over $40 billion poured into AI biopharma ventures since 2016, according to PitchBook. However, despite its promise, the technology has yet to deliver substantial evidence of its effectiveness in real-world applications. Researchers note that while AI excels at identifying potential drug candidates, it struggles to validate these predictions within the complexities of human biology. This challenge is largely attributed to the limitations of cellular data sets, which are often insufficient or too disorganized to support robust conclusions. Despite these hurdles, some late-stage applications of AI in drug development are already in progress. Biotech venture capitalists, such as those interviewed by Axios, remain optimistic, though they acknowledge the need for tangible results. Advocates for AI in healthcare argue that slowing its advancement could delay the development of life-saving treatments, emphasizing the importance of balancing innovation with safety concerns.